Barclays reiterated coverage on Evolus with a new price target
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays reiterated coverage of Evolus with a rating of Underweight and set a new price target of $7.00 from $8.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $10.00 → $16.00 | Equal Weight → Overweight | Barclays |
| 6/23/2022 | $18.00 | Buy | Needham |
| 5/12/2022 | $8.00 → $10.00 | Underweight → Equal Weight | Barclays |
| 1/20/2022 | $11.00 | Hold → Buy | Truist |
| 11/3/2021 | $22.00 → $15.00 | Buy | HC Wainwright & Co. |
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The
Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense
S-8 - Evolus, Inc. (0001570562) (Filer)
10-K - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously
Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00
Barclays upgraded Evolus from Underweight to Equal Weight and set a new price target of $10.00 from $8.00 previously
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati
Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:
Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a tel
Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and Launch Expected by September 2025 Narrows Full-Year 2024 Net Revenue Guidance to $260 Million to $266 Million, Representing Year-Over-Year Growth of 29% to 32% Reaffirms Non-GAAP Profitability1 in Q4 2024 and Full Year 2025
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)